DK2292802T3 - Udvikling af mutationer, der er anvendelige til svækkelse af dengue-vira og kimære dengue-vira - Google Patents

Udvikling af mutationer, der er anvendelige til svækkelse af dengue-vira og kimære dengue-vira Download PDF

Info

Publication number
DK2292802T3
DK2292802T3 DK10181804.5T DK10181804T DK2292802T3 DK 2292802 T3 DK2292802 T3 DK 2292802T3 DK 10181804 T DK10181804 T DK 10181804T DK 2292802 T3 DK2292802 T3 DK 2292802T3
Authority
DK
Denmark
Prior art keywords
virus
viruses
mutations
cells
dengue
Prior art date
Application number
DK10181804.5T
Other languages
English (en)
Inventor
Stephen S Whitehead
Brian R Murphy
Kathryn A Hanley
Joseph E Blaney Jr
Ching-Juh Lai
Original Assignee
Us Gov Health & Human Serv
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Us Gov Health & Human Serv filed Critical Us Gov Health & Human Serv
Application granted granted Critical
Publication of DK2292802T3 publication Critical patent/DK2292802T3/da

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • C12N7/04—Inactivation or attenuation; Producing viral sub-units
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A61K2039/5252—Virus inactivated (killed)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A61K2039/5254—Virus avirulent or attenuated
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A61K2039/5256—Virus expressing foreign proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
    • A61K2039/575—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2 humoral response
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/70—Multivalent vaccine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/295—Polyvalent viral antigens; Mixtures of viral and bacterial antigens
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/24011—Flaviviridae
    • C12N2770/24111—Flavivirus, e.g. yellow fever virus, dengue, JEV
    • C12N2770/24121—Viruses as such, e.g. new isolates, mutants or their genomic sequences
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/24011—Flaviviridae
    • C12N2770/24111—Flavivirus, e.g. yellow fever virus, dengue, JEV
    • C12N2770/24134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/24011—Flaviviridae
    • C12N2770/24111—Flavivirus, e.g. yellow fever virus, dengue, JEV
    • C12N2770/24151—Methods of production or purification of viral material
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/24011—Flaviviridae
    • C12N2770/24111—Flavivirus, e.g. yellow fever virus, dengue, JEV
    • C12N2770/24161—Methods of inactivation or attenuation
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/24011—Flaviviridae
    • C12N2770/24111—Flavivirus, e.g. yellow fever virus, dengue, JEV
    • C12N2770/24161—Methods of inactivation or attenuation
    • C12N2770/24162—Methods of inactivation or attenuation by genetic engineering
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/24011—Flaviviridae
    • C12N2770/24111—Flavivirus, e.g. yellow fever virus, dengue, JEV
    • C12N2770/24161—Methods of inactivation or attenuation
    • C12N2770/24163—Methods of inactivation or attenuation by chemical treatment
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/24011—Flaviviridae
    • C12N2770/24111—Flavivirus, e.g. yellow fever virus, dengue, JEV
    • C12N2770/24171—Demonstrated in vivo effect
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/70—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving virus or bacteriophage
    • C12Q1/701—Specific hybridization probes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/156—Polymorphic or mutational markers
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/005—Assays involving biological materials from specific organisms or of a specific nature from viruses
    • G01N2333/08—RNA viruses
    • G01N2333/18—Togaviridae; Flaviviridae
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2500/00—Screening for compounds of potential therapeutic value
    • G01N2500/10—Screening for compounds of potential therapeutic value involving cells
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Virology (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Medicinal Chemistry (AREA)
  • Microbiology (AREA)
  • Biochemistry (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Biomedical Technology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Biophysics (AREA)

Claims (17)

1. Dengue-virus omfattende en glycinmutation i den aminosyrestilling, der svarer til aminosyrestilling 2664 i SEQ ID NO: 19.
2. Dengue-virus ifølge krav 1, som endvidere omfatter A30-mutationen.
3. Dengue-virus ifølge krav 1, hvor dengue-virusset er et dengue-virus type 1, et dengue-virus type 2, et dengue-virus type 3 eller et dengue-virus type 4.
4. Dengue-virus ifølge krav 1, hvor dengue-virusset er et kimært virus.
5. Kimært virus ifølge krav 4 med et dengue-1-skelet, et dengue-2-skelet, et dengue-3-skelet eller et dengue-4-skelet.
6. Farmaceutisk sammensætning omfattende et farmakologisk acceptabelt bærestof og et dengue-virus ifølge et hvilket som helst af kravene 1 til 5.
7. Sæt omfattende en farmaceutisk sammensætning ifølge krav 6 i en pakke eller en doseringsindretning og instruktioner til indgivelse.
8. Anvendelse af et dengue-virus ifølge et hvilket som helst af kravene 1 til 5 og et farmaceutisk acceptabelt bærestof til fremstilling af en farmaceutisk sammensætning til frembringelse af neutraliserende antistoffer mod dengue-virus, hvor sammensætningen skal indgives til et individ.
9. Farmaceutisk sammensætning omfattende et dengue-virus ifølge et hvilket som helst af kravene 1 til 5 og et farmaceutisk acceptabelt bærestof til anvendelse ved frembringelse af neutraliserende antistoffer mod dengue-virus, hvor sammensætningen skal indgives til et individ.
10. Anvendelse ifølge krav 8 eller farmaceutisk sammensætning ifølge krav 9, hvor indgivelsen foregår ved subkutan, intradermal eller intramuskulær injektion.
11. Tetravalent vaccine omfattende et farmakologisk acceptabelt bærestof og et dengue-virus ifølge et hvilket som helst af kravene 1 til 5.
12. Svækket levende vaccine omfattende et farmakologisk acceptabelt bærestof og et dengue-virus ifølge et hvilket som helst af kravene 1 til 5.
13. Svækket levende vaccine ifølge krav 12 i enhedsdosisform med ca. 102-109 plaquedannende enheder (PFU)/ml.
14. Inaktiveret vaccine omfattende et farmakologisk acceptabelt bærestof og et dengue-virus ifølge et hvilket som helst af kravene 1 til 5.
15. Inaktiveret vaccine ifølge krav 14 i enhedsdosisform med fra ca. 0,1 til 50 pg E-protein/ml.
16. Nukleinsyremolekyle, der koder for et dengue-virus ifølge et hvilket som helst af kravene 1 til 5, hvor nukleinsyremolekylet er et cDNA-molekyle eller et RNA-molekyle.
17. Fremgangsmåde til fremstilling af et dengue-virus omfattende (a) syntese in vitro af viral genomisk RNA i fuld længde under anvendelse af et cDNA-molekyle, der koder for et dengue-virus ifølge et hvilket som helst af kravene 1 til 5; (b) transfektion af dyrkede celler med den virale genomiske RNA til fremstilling af virus; og (c) isolering af virusset fra de dyrkede celler.
DK10181804.5T 2001-05-22 2002-05-22 Udvikling af mutationer, der er anvendelige til svækkelse af dengue-vira og kimære dengue-vira DK2292802T3 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US29304901P 2001-05-22 2001-05-22
EP02739358A EP1402075B1 (en) 2001-05-22 2002-05-22 Development of mutations useful for attenuating dengue viruses and chimeric dengue viruses

Publications (1)

Publication Number Publication Date
DK2292802T3 true DK2292802T3 (da) 2015-03-09

Family

ID=23127420

Family Applications (4)

Application Number Title Priority Date Filing Date
DK02739358.6T DK1402075T3 (da) 2001-05-22 2002-05-22 Udvikling af egnede mutationer til svækkelse af dengue-vira samt kimære dengue-vira
DK10181786.4T DK2290109T3 (da) 2001-05-22 2002-05-22 Udvikling af mutationer, der er anvendelige til svækkelse af dengue-vira samt kimære dengue-vira
DK10181776.5T DK2290108T3 (da) 2001-05-22 2002-05-22 Udvikling af mutationer, der er anvendelige til svækkelse af dengue-vira, samt kimære dengue-vira
DK10181804.5T DK2292802T3 (da) 2001-05-22 2002-05-22 Udvikling af mutationer, der er anvendelige til svækkelse af dengue-vira og kimære dengue-vira

Family Applications Before (3)

Application Number Title Priority Date Filing Date
DK02739358.6T DK1402075T3 (da) 2001-05-22 2002-05-22 Udvikling af egnede mutationer til svækkelse af dengue-vira samt kimære dengue-vira
DK10181786.4T DK2290109T3 (da) 2001-05-22 2002-05-22 Udvikling af mutationer, der er anvendelige til svækkelse af dengue-vira samt kimære dengue-vira
DK10181776.5T DK2290108T3 (da) 2001-05-22 2002-05-22 Udvikling af mutationer, der er anvendelige til svækkelse af dengue-vira, samt kimære dengue-vira

Country Status (8)

Country Link
US (10) US7226602B2 (da)
EP (5) EP2940154B1 (da)
AU (2) AU2002312011B2 (da)
BR (2) BRPI0209943B8 (da)
CA (5) CA3060687C (da)
DK (4) DK1402075T3 (da)
ES (4) ES2523168T3 (da)
WO (1) WO2002095075A1 (da)

Families Citing this family (34)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK1554301T3 (da) 2002-05-03 2011-01-24 Us Health Dengue-vaccine med en fælles udeladelse af 30 nukleotider i Dengue-typerne 1's og 2's3'UTR
US7851194B2 (en) * 2004-06-14 2010-12-14 The United States Of America As Represented By The Department Of Health And Human Services West Nile viruses with mutations in the 3′ terminal stem and loop secondary structure for use as live virus vaccines
AU2006239954A1 (en) 2005-04-24 2006-11-02 Acambis Inc. Recombinant flavivirus vaccines
CN101238144B (zh) 2005-06-17 2012-09-05 赛诺菲巴斯德有限公司 登革血清型1减毒株
WO2006134443A1 (en) 2005-06-17 2006-12-21 Sanofi Pasteur Dengue serotype 2 attenuated strain
CU23578A1 (es) * 2005-09-16 2010-09-30 Ct Ingenieria Genetica Biotech Proteína de la cápsida del virus dengue inductora de respuesta protectora y composición vacunal
FR2906724B1 (fr) 2006-10-04 2009-03-20 Sanofi Pasteur Sa Methode d'immunisation contre les 4 serotypes de la dengue.
US20100316670A1 (en) * 2007-06-14 2010-12-16 Blaney Joseph E Chimeric sle/dengue type 4 antigenic viruses
CA2716399C (en) 2008-03-05 2020-07-21 Pierre Chouvenc Process for stabilizing an adjuvant containing vaccine composition
WO2009152147A2 (en) * 2008-06-09 2009-12-17 La Jolla Institute For Allergy And Immunology Compositions and methods for dengue virus (dv) treatment and vaccination
EP2143440A1 (fr) 2008-07-09 2010-01-13 Sanofi Pasteur Agent stabilisant et composition vaccinale comprenant un ou plusieurs flavivirus vivants atténués
PE20110992A1 (es) 2009-02-17 2012-02-12 Glaxosmithkline Biolog Sa Composicion inmunogenica que comprende un antigeno del virus del dengue
WO2010130748A1 (en) * 2009-05-12 2010-11-18 Tibotec Pharmaceuticals Method for identifying inhibitors against dengue virus
EP2438198A4 (en) 2009-06-01 2014-05-14 Inviragen Inc COMPOSITIONS AND METHODS FOR THE DELIVERY OF VACCINES AGAINST DENGUE VIRUS
US8968996B2 (en) 2009-06-01 2015-03-03 Takeda Vaccines, Inc. Compositions and methods for rapid immunization against dengue virus
WO2010144961A1 (en) * 2009-06-17 2010-12-23 Stephen Woodford Determining haemodynamic performance
CA2770888C (en) 2009-08-31 2020-04-14 Gen-Probe Incorporated Dengue virus assay
EP2353609A1 (en) 2010-02-04 2011-08-10 Sanofi Pasteur Immunization compositions and methods
US10308689B2 (en) 2010-06-24 2019-06-04 La Jolla Institute For Allergy And Immunology Dengue virus (DV) polypeptide sequences, T cell epitopes and methods and uses thereof
US8895028B2 (en) 2012-07-20 2014-11-25 Arbovax, Inc. Methods and compositions for dengue virus 3 (DV3) infectious clone
MY168959A (en) 2012-07-24 2019-01-28 Sanofi Pasteur Vaccine compositions for the prevention of dengue virus infection
AU2014281713A1 (en) 2013-06-21 2015-11-12 Merck Sharp & Dohme Corp. Dengue virus vaccine compositions and methods of use thereof
CA2938590C (en) 2014-02-11 2023-10-17 Visterra, Inc. Antibody molecules to dengue virus and uses thereof
WO2016037187A1 (en) * 2014-09-05 2016-03-10 The Research Foundation For The State University Of New York Recoded arbovirus and vaccines
US10449243B2 (en) 2014-12-22 2019-10-22 Merck Sharp & Dohme Corp. Dengue virus vaccine compositions and methods of use thereof
US10920288B2 (en) * 2015-01-16 2021-02-16 Takeda Vaccines, Inc. Detection of particle-contained reverse transcriptase activity
WO2017023839A1 (en) 2015-08-03 2017-02-09 The United States Of America As Represented By The Secretary Of The Navy Immune enhancing recombinant dengue protein
WO2017109698A1 (en) 2015-12-22 2017-06-29 Glaxosmithkline Biologicals Sa Immunogenic formulation
AU2017230112A1 (en) 2016-03-11 2018-10-04 The Johns Hopkins University Live attenuated Zika virus vaccine
TWI763660B (zh) 2016-03-25 2022-05-11 美商威特拉公司 登革病毒的抗體分子之配方設計
BR112018071176A2 (pt) 2016-04-14 2019-02-12 National University Of Singapore método rápido de produção de vacinas vivas atenuadas
WO2018129160A1 (en) 2017-01-06 2018-07-12 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Live attenuated flavivirus vaccines and methods of using and making same
AU2018346724A1 (en) 2017-10-05 2020-05-14 Sanofi Pasteur Compositions for booster vaccination against dengu
CN117752780A (zh) 2017-12-07 2024-03-26 默沙东有限责任公司 登革病毒疫苗组合物的制剂

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH0832638B2 (ja) 1989-05-25 1996-03-29 カイロン コーポレイション サブミクロン油滴乳剤を含んで成るアジュバント製剤
US5494671A (en) 1990-08-27 1996-02-27 The United States Of America As Represented By The Department Of Health And Human Services C-terminally truncated dengue and Japanese encephalitis virus envelope proteins
GB9513371D0 (en) 1995-06-30 1995-09-06 Biocine Spa Immunogenic detoxified mutant toxins
IT1253009B (it) 1991-12-31 1995-07-10 Sclavo Ricerca S R L Mutanti immunogenici detossificati della tossina colerica e della tossina lt, loro preparazione ed uso per la preparazione di vaccini
GB9326174D0 (en) 1993-12-22 1994-02-23 Biocine Sclavo Mucosal adjuvant
US6074865A (en) * 1995-07-20 2000-06-13 The United States Of America As Represented By The Secretary Of The Army Recombinant dengue virus DNA fragment
US6455509B1 (en) * 1996-06-04 2002-09-24 The United States Of America As Represented By The Secretary Of The Navy Dengue nucleic acid vaccines that induce neutralizing antibodies
US6537557B1 (en) * 1999-03-26 2003-03-25 The United States Of America As Represented By The Secretary Of The Army Attenuated dengue-4 virus vaccine
KR100721745B1 (ko) * 1999-03-26 2007-05-25 왈터 리드 아미 인스티튜트 오브 리써치 다가 뎅기 바이러스 백신

Also Published As

Publication number Publication date
US10500264B2 (en) 2019-12-10
BR122019026154B8 (pt) 2021-07-27
EP2290108A2 (en) 2011-03-02
CA2448329A1 (en) 2002-11-28
EP2290109A2 (en) 2011-03-02
CA2755964A1 (en) 2002-11-28
DK2290108T3 (da) 2014-10-20
CA3060687A1 (en) 2002-11-28
BR0209943A (pt) 2004-03-30
ES2523168T3 (es) 2014-11-21
USRE45053E1 (en) 2014-07-29
ES2533085T3 (es) 2015-04-07
BRPI0209943B1 (pt) 2020-10-13
US20050010043A1 (en) 2005-01-13
USRE45123E1 (en) 2014-09-09
DK2290109T3 (da) 2014-11-10
BR122019026154B1 (pt) 2020-11-24
EP1402075A4 (en) 2005-05-11
BRPI0209943B8 (pt) 2021-05-25
CA3114957A1 (en) 2002-11-28
CA3060687C (en) 2021-05-04
USRE45016E1 (en) 2014-07-15
US11318196B2 (en) 2022-05-03
EP1402075B1 (en) 2012-11-14
AU2002312011B2 (en) 2008-04-24
EP2292802A2 (en) 2011-03-09
EP2290108B1 (en) 2014-07-23
CA2448329C (en) 2011-10-25
CA2966716C (en) 2019-11-26
EP2292802A3 (en) 2011-03-23
US7560118B2 (en) 2009-07-14
AU2008203275B2 (en) 2011-11-10
CA2755964C (en) 2017-06-27
CA2966716A1 (en) 2002-11-28
AU2008203275A1 (en) 2008-08-14
US20150064214A1 (en) 2015-03-05
CA3114957C (en) 2022-02-08
EP2290109A3 (en) 2011-03-16
EP2292802B1 (en) 2015-01-14
EP2940154B1 (en) 2019-05-22
DK1402075T3 (da) 2013-02-11
EP2290108A3 (en) 2011-03-09
EP2290109B1 (en) 2014-08-13
US8632782B2 (en) 2014-01-21
WO2002095075A1 (en) 2002-11-28
US20070092534A1 (en) 2007-04-26
US20090263424A1 (en) 2009-10-22
US20180008693A1 (en) 2018-01-11
EP1402075A1 (en) 2004-03-31
US8039003B2 (en) 2011-10-18
EP2940154A1 (en) 2015-11-04
US7226602B2 (en) 2007-06-05
US20200085939A1 (en) 2020-03-19
US20120114694A1 (en) 2012-05-10
US9707287B2 (en) 2017-07-18
ES2512715T3 (es) 2014-10-24
ES2399420T3 (es) 2013-04-01

Similar Documents

Publication Publication Date Title
US11318196B2 (en) Attenuated mutant dengue viruses comprising a mutation in the NS5 non-structural protein
AU2002312011A1 (en) Development of mutations useful for attenuating dengue viruses and chimeric dengue viruses
AU2020200863B2 (en) Development of mutations useful for attenuating dengue viruses and chimeric dengue viruses